AbCellera
a potential first in class antibody therapy for metabolic and endocrine conditions | AbCellera
Company
Deck Type
Sector
Industry
Deck date
February 2024
Slide
7 of 22
Similar slides by AbCellera
See diffirences between slides (animation)
Investor Presentation
February 2024
we are advancing an internal pipeline of potential first in class and best in class assets as a top priority to drive growth | AbCellera
Investor Conference
January 2024
a potential first in class antibody therapy for metabolic and endocrine conditions asset derived from our ion channel platform | AbCellera
Investor Conference
January 2024
advancing an internal pipeline of potential first in class and best in class assets is a top priority to drive growth first two submissions anticipated in we intend take additional development candidates into enabling studies in in non dilutive funding from governments canada atopic dermatitis or undisclosed | AbCellera
Related slides by other companies
Adagio Therapeutics
Investor Conference
March 2023
is one of many antibodies in robust pipeline | Adagio Therapeutics
argenx SE
Results
July 2021
our pipeline starts with our immunology innovation program | argenx SE
Moolec Science
Results
December 2023
pipeline status | Moolec Science
Immatics
Investor Presentation
November 2023
is where the data is | Immatics
Other recent decks by AbCellera
See all presentations (23 decks)
Investor Conference
January 2024
Results
November 2023
Investor Presentation
November 2023
Investor Presentation
November 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2023 Slidebook.io